Table 1.
Baseline Characteristics of Rectal Cancer Patients
| All Patients (n) | 911 |
|---|---|
| Gender (n (%)) | |
| Female | 316 (34.7) |
| Male | 595 (65.3) |
| Age (years) (mean (SD)) | 55.30 (11.33) |
| Age (n (%)) | |
| <60 years | 571 (62.7) |
| ≥60 years | 340 (37.3) |
| cT classification (n (%)) | |
| cT2 | 48 (5.3) |
| cT3 | 338 (37.1) |
| cT4 | 525 (57.6) |
| cN classification (n (%)) | |
| Negative | 90 (9.9) |
| Positive | 821 (90.1) |
| Pretreatment CEA (n (%)) | |
| Normal | 513 (56.3) |
| Elevated | 398 (43.7) |
| Pretreatment CA199 (n (%)) | |
| Normal | 786 (86.3) |
| Elevated | 125 (13.7) |
| Location (n (%)) | |
| Low | 376 (41.3) |
| Middle | 464 (50.9) |
| High | 71 (7.8) |
| Chemotherapy (n (%)) | |
| CapeOx | 232 (25.5) |
| Capecitabine | 524 (57.5) |
| 5-Fu based | 155 (17.0) |
| Radiotherapy (n (%)) | |
| 3DRT | 292 (32.1) |
| IMRT | 619 (67.9) |
| Surgery (n (%)) | |
| NO APR | 813 (89.2) |
| APR | 98 (10.8) |
| TLN (n (%)) | |
| <12 | 420(46.1) |
| ≥12 | 491(53.9) |
| Posttreatment CEA (n (%)) | |
| Normal | 781 (85.7) |
| Elevated | 130 (14.3) |
| Posttreatment CA199 (n (%)) | |
| Normal | 860 (94.4) |
| Elevated | 51 (5.6) |
| pT classification (n (%)) | |
| pT0 | 187 (20.5) |
| pT1 | 55 (6.0) |
| pT2 | 235 (25.8) |
| pT3 | 377 (41.4) |
| pT4 | 57 (6.3) |
| pN classification (n (%)) | |
| pN0 | 665 (73.0) |
| pN1 | 184 (20.2) |
| pN2 | 62 (6.8) |
| pCR (n (%)) | |
| NO | 733(80.5) |
| YES | 178(19.5) |
| Adjuvant chemotherapy (n (%)) | |
| NO | 198 (21.7) |
| YES | 713 (78.3) |
| Status (n (%)) | |
| Censored | 736 (80.8) |
| Death | 175 (19.2) |
| Follow-up time (months, median(IQR)) | 51.4(37.7, 71.5) |
Abbreviations: 3DRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiation therapy; APR, abdominoperineal resection; TLN, the total number of examined lymph node; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9; IQR, interquartile range.